1.Cost-effective analysis of dual therapy in epilepsy, a study from India
Sarita Goyal ; DC Dhasmana ; Deepak Goel ; MC Gupta ; Taruna Sharma
Neurology Asia 2011;16(4):309-314
Background and Objective: For improving overall care in epileptic patients, careful evaluation of
pharmacotherapy, seizure control, quality of life (QOL) and cost effectiveness are helpful but such
data are relatively meagre from developing countries. The present study was undertaken to audit all
these said factors with different drug combinations comparing older with newer drugs in the setting
of a tertiary care epilepsy hospital in India. Methods: Forty patients were divided into four treatment
groups, of ten each which were valproic acid + lamotrigine (Group-I), valproic acid+ clonazepam
(Group-II), oxcarbazepine + clobazam (Group-III) and phenobarbitone + phenytoin (Group-IV), based
on most commonly used dual therapy in local clinical practice. The patients were followed at monthly
intervals for six months. Effi cacy was assessed by reduction in seizure frequency, QOL was assessed
by using an adapted version of 31- items questionnaire QOLIE-31 (quality of life in epilepsy) and
cost effectiveness was calculated as ratio of direct cost of medicine and improvement in quality of
life. Results: There was a signifi cant reduction in seizure frequency and improvement in QOL in all
four groups at 2nd and 6th months. Cost-effectiveness analysis at the end showed that group-IV paid
the least for same improvement in QOL.
Conclusion: Older drugs are equally effi cacious as compared to newer in controlling seizure frequency
and improving QOL, but are more cost effective.
2.p40 in metastatic pulmonary trophoblastic tumour: potential diagnostic pitfall on histopathology
Archana George Vallonthaiel ; Ritika Walia ; Raja Pramanik ; MC Sharma ; Deepali Jain
The Malaysian Journal of Pathology 2017;39(2):175-179
p40, one of the two isomers of p63, is nowadays widely used for diagnosis of squamous cell
carcinoma, especially in subtyping non-small cell carcinoma on lung biopsies. We describe a case
in which lung tumour was misdiagnosed as squamous cell carcinoma due to p40 immunopositivity.
A 36-year-old lady presented with cough and left sided chest pain of 2 months duration. Chest
imaging revealed a lesion in left lower lobe of the lung and biopsy was suggestive of squamous
cell carcinoma. However, past history revealed amputation of great toe for non-healing discharging
ulcer which on histopathology was diagnosed as choriocarcinoma. She also had a history of
hysterectomy five years ago, details of which were not available. Post-amputation β-hCG levels
were high and she had been treated with multimodality chemotherapy for choriocarcinoma. She
had good response to chemotherapy initially, however became resistant later on. Review of the
lung biopsy in the light of the past history along with extensive literature review led to the final
diagnosis of metastatic trophoblastic tumour to lung. Hence, awareness that p40 immunopositivity
can be seen in trophoblastic tumours is essential to avoid misdiagnosis, especially in sites like the
lung where squamous cell carcinoma is common.